文献速递核素与放射性配体治疗

177Lu-DOTATATE再治疗进展性神经内分泌肿瘤的有效性与安全性:美国回顾性真实世界研究

Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States.
PubMed 文献 · J Nucl Med · 2024-05-01

美国单中心2010至2020年回顾性图表审查31例接受177Lu-DOTATATE初始治疗(最多4周期)后进展、距初次治疗结束至少6个月并再治疗至少1周期的晚期神经内分泌肿瘤成人患者,评估有效性与安全性。再治疗后部分缓解23%、疾病稳定45%,再治疗后中位无进展生存期9.6个月、中位总生存期12.6个月;再治疗后临床显著血液毒性3例,未见3至4级肾毒性。

要点

  • 再治疗后部分缓解23%、疾病稳定45%,中位无进展生存期9.6个月。
  • 再治疗后中位总生存期12.6个月,临床显著血液毒性3例。
  • 再治疗期间未见3级或4级肾毒性。

核心结论

  • 初始177Lu-DOTATATE治疗后进展的进展性神经内分泌肿瘤患者,再治疗似乎耐受良好并提供疾病控制。

研究设计与样本

  • 美国单中心回顾性图表审查,纳入2010至2020年接受177Lu-DOTATATE初始治疗最多4周期、进展后距初次治疗结束至少6个月并再治疗至少1周期的晚期神经内分泌肿瘤成人患者31例。
  • 再治疗患者中61%为男性、94%为白人;患者总体接受中位6周期(初始4周期加再治疗2周期),平均给药活度41.9 GBq。
  • 2例患者在再治疗后再次进展并间隔至少6个月后接受额外再治疗(分别为1周期和2周期)。

主要发现

  • 初始治疗后最佳疗效为部分缓解35%、疾病稳定65%;再治疗后部分缓解23%、疾病稳定45%。
  • 初始治疗后中位无进展生存期20.2个月,再治疗后中位无进展生存期9.6个月。
  • 初始治疗后中位总生存期42.6个月,再治疗后中位总生存期12.6个月。
  • 初始治疗和再治疗期间血液学参数均显著下降,但恢复后初始治疗前与再治疗前数值差异很小。
  • 初始治疗后临床显著血液毒性1例、再治疗后3例;未见3级或4级肾毒性。

关键数值与推荐

  • 疗效按RECIST 1.1评价,毒性按常见不良事件评价标准5.0版定义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advanced neuroendocrine tumors (NETs) are associated with a poor prognosis. A regimen of 4 cycles of 177Lu-DOTATATE has been shown to improve both progression-free survival (PFS) and overall survival (OS) in patients with advanced NETs. To the best of our knowledge, this is the first study in the United States to evaluate the effectiveness and safety of additional cycles of 177Lu-DOTATATE therapy in patients with progressive NETs. Methods: This was a retrospective chart review of adults with advanced NETs. The patients had undergone initial treatment with up to 4 cycles of 177Lu-DOTATATE and, after disease progression and a period of at least 6 mo since the end of the initial treatment, were retreated with at least 1 additional cycle at a single center (2010-2020). Patient characteristics, treatment patterns, and clinical outcomes were evaluated descriptively. Response was evaluated according to RECIST 1.1; toxicity was defined using criteria from Common Terminology Criteria for Adverse Events, version 5.0. Kaplan-Meier plots were used to evaluate PFS and OS. Results: Of the 31 patients who received 177Lu-DOTATATE retreatment, 61% were male and 94% were White. Overall, patients received a median of 6 cycles (4 initial cycles and 2 retreatment cycles), and the mean administered activity was 41.9 GBq. Two patients also went on to receive additional retreatment (1 and 2 cycles, individually) after a second period of at least 6 mo and progression after retreatment. Best responses of partial response and stable disease were observed in 35% and 65% of patients after the initial treatment and 23% and 45% of patients after retreatment, respectively. The median PFS after the initial treatment was 20.2 mo and after retreatment was 9.6 mo. The median OS after the initial treatment was 42.6 mo and after retreatment was 12.6 mo. Hematologic parameters decreased significantly during both the initial treatment and retreatment but recovered such that there was little difference between the values before the initial treatment and before the retreatment. Clinically significant hematotoxicity occurred in 1 and 3 patients after the initial treatment and retreatment, respectively. No grade 3 or 4 nephrotoxicity was observed. Conclusion: Retreatment with 177Lu-DOTATATE after progression appeared to be well tolerated and offered disease control in patients with progressive NETs after initial 177Lu-DOTATATE treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Delpassand ES, Yazdi SM, Ghantoji S, et al. Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States. J Nucl Med. 2024. PMID: 38514088. doi:10.2967/jnumed.123.265703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。